VEW 2022: New dark adaptation modality and other pipeline updates from Heru


Brandon Barber, chief marketing officer at Heru, shares about the company's new dark adaptation modality, which they announced during the 2022 Vision Expo West, as well as other advancements in the pipeline.

Brandon Barber, chief marketing officer for Heru, sat down with Optometry Times® editor, Kassi Jackson, to share about the company's new AMD portfolio expansion, and other items in the pipeline.

Related: Heru expands AMD portfolio with new launch

Key takeaways from the interview:

  • Heru's latest dark adaptation modality. This new technology allows Heru to offer the only AMD portfolio available on the market.
  • The company is providing cloud-based updates for their platform on a weekly and monthly basis to improve customer and patient outcomes.
  • New therapeutic technology is coming out of their research facility in Bascom Palmer Eye Institute, including AR platform adaptations to improve eye defects that lead to limited vision for patients.
  • Barber said that in the next 24 to 36 months, there will be advancements in the areas of AR and VR.
  • These new and coming advancements improve patient experience, as well as will improve the ability for optometrists to "speed more patients through their practice," according to Barber.
Recent Videos
EyeCon Co-chair Oluwatosin U. Smith, MD talks passion for research and education in ophthalmology
Eyerie Academics cofounders discuss the organization's future and preparing optometric students
Charissa Lee, OD, MBA, FAAO, talks DEI in leadership roles in optometry
Spencer Johnson, OD, FAAO, overviews his talk on laser procedures at Optometry's Meeting
GWCO past-president and treasurer outline the 2024 Congress event in October
Derek Bryant, 2024 AOSA president
Kurt Moody, OD, FAAO, describes how to fit multifocal contact lenses in a way that patients love
Drs Erin Draper and Chris Cuk outline the important role optometrists have in spotting neurodegenerative disease in patients
Susan Gromacki, OD, MS, FAAO, FSLS
© 2024 MJH Life Sciences

All rights reserved.